Crinetics shares are trading higher after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly.
Portfolio Pulse from Benzinga Newsdesk
Crinetics Pharmaceuticals' shares are trading higher after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly.
September 11, 2023 | 9:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Crinetics Pharmaceuticals' stock is trading higher due to positive results from the Phase 3 PATHFNDR-1 study of paltusotine.
The positive results from the Phase 3 PATHFNDR-1 study of paltusotine, a drug developed by Crinetics Pharmaceuticals, have led to an increase in the company's stock price. This is because successful clinical trials often lead to increased investor confidence and potential future revenues from the sale of the drug.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100